Telesis Bio, Inc.
Telesis Bio, Inc. TBIO Peers
See (TBIO) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| TBIO | $0.30 | +200.00% | 532.8K | -0.01 | -$30.42 | N/A |
| ABT | $136.01 | +1.21% | 236.6B | 17.68 | $7.69 | +1.68% |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| BSX | $107.41 | +0.83% | 158.8B | 78.37 | $1.37 | N/A |
| SYK | $395.63 | +0.53% | 151.2B | 53.54 | $7.39 | +0.84% |
| MDT | $87.17 | +1.34% | 111.7B | 24.15 | $3.61 | +3.22% |
| EW | $78.21 | +0.00% | 45.9B | 32.31 | $2.42 | N/A |
| DXCM | $87.29 | +1.11% | 34.2B | 65.63 | $1.33 | N/A |
| STE | $240.22 | +0.60% | 23.6B | 38.99 | $6.16 | +0.95% |
| PHG | $23.98 | -0.66% | 22.2B | 79.93 | $0.30 | +3.70% |
Stock Comparison
TBIO vs ABT Comparison
TBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TBIO stands at 532.8K. In comparison, ABT has a market cap of 236.6B. Regarding current trading prices, TBIO is priced at $0.30, while ABT trades at $136.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TBIO currently has a P/E ratio of -0.01, whereas ABT's P/E ratio is 17.68. In terms of profitability, TBIO's ROE is -2.80%, compared to ABT's ROE of +0.31%. Regarding short-term risk, TBIO is less volatile compared to ABT. This indicates potentially lower risk in terms of short-term price fluctuations for TBIO.
TBIO vs BSX-PA Comparison
TBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TBIO stands at 532.8K. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, TBIO is priced at $0.30, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TBIO currently has a P/E ratio of -0.01, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, TBIO's ROE is -2.80%, compared to BSX-PA's ROE of +0.10%. Regarding short-term risk, TBIO is less volatile compared to BSX-PA. This indicates potentially lower risk in terms of short-term price fluctuations for TBIO.
TBIO vs BSX Comparison
TBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TBIO stands at 532.8K. In comparison, BSX has a market cap of 158.8B. Regarding current trading prices, TBIO is priced at $0.30, while BSX trades at $107.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TBIO currently has a P/E ratio of -0.01, whereas BSX's P/E ratio is 78.37. In terms of profitability, TBIO's ROE is -2.80%, compared to BSX's ROE of +0.10%. Regarding short-term risk, TBIO is less volatile compared to BSX. This indicates potentially lower risk in terms of short-term price fluctuations for TBIO.
TBIO vs SYK Comparison
TBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TBIO stands at 532.8K. In comparison, SYK has a market cap of 151.2B. Regarding current trading prices, TBIO is priced at $0.30, while SYK trades at $395.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TBIO currently has a P/E ratio of -0.01, whereas SYK's P/E ratio is 53.54. In terms of profitability, TBIO's ROE is -2.80%, compared to SYK's ROE of +0.11%. Regarding short-term risk, TBIO is less volatile compared to SYK. This indicates potentially lower risk in terms of short-term price fluctuations for TBIO.
TBIO vs MDT Comparison
TBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TBIO stands at 532.8K. In comparison, MDT has a market cap of 111.7B. Regarding current trading prices, TBIO is priced at $0.30, while MDT trades at $87.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TBIO currently has a P/E ratio of -0.01, whereas MDT's P/E ratio is 24.15. In terms of profitability, TBIO's ROE is -2.80%, compared to MDT's ROE of +0.10%. Regarding short-term risk, TBIO is less volatile compared to MDT. This indicates potentially lower risk in terms of short-term price fluctuations for TBIO.
TBIO vs EW Comparison
TBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TBIO stands at 532.8K. In comparison, EW has a market cap of 45.9B. Regarding current trading prices, TBIO is priced at $0.30, while EW trades at $78.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TBIO currently has a P/E ratio of -0.01, whereas EW's P/E ratio is 32.31. In terms of profitability, TBIO's ROE is -2.80%, compared to EW's ROE of +0.49%. Regarding short-term risk, TBIO is less volatile compared to EW. This indicates potentially lower risk in terms of short-term price fluctuations for TBIO.
TBIO vs DXCM Comparison
TBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TBIO stands at 532.8K. In comparison, DXCM has a market cap of 34.2B. Regarding current trading prices, TBIO is priced at $0.30, while DXCM trades at $87.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TBIO currently has a P/E ratio of -0.01, whereas DXCM's P/E ratio is 65.63. In terms of profitability, TBIO's ROE is -2.80%, compared to DXCM's ROE of +0.24%. Regarding short-term risk, TBIO is less volatile compared to DXCM. This indicates potentially lower risk in terms of short-term price fluctuations for TBIO.
TBIO vs STE Comparison
TBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TBIO stands at 532.8K. In comparison, STE has a market cap of 23.6B. Regarding current trading prices, TBIO is priced at $0.30, while STE trades at $240.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TBIO currently has a P/E ratio of -0.01, whereas STE's P/E ratio is 38.99. In terms of profitability, TBIO's ROE is -2.80%, compared to STE's ROE of +0.09%. Regarding short-term risk, TBIO is less volatile compared to STE. This indicates potentially lower risk in terms of short-term price fluctuations for TBIO.
TBIO vs PHG Comparison
TBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TBIO stands at 532.8K. In comparison, PHG has a market cap of 22.2B. Regarding current trading prices, TBIO is priced at $0.30, while PHG trades at $23.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TBIO currently has a P/E ratio of -0.01, whereas PHG's P/E ratio is 79.93. In terms of profitability, TBIO's ROE is -2.80%, compared to PHG's ROE of +0.03%. Regarding short-term risk, TBIO is less volatile compared to PHG. This indicates potentially lower risk in terms of short-term price fluctuations for TBIO.
TBIO vs PODD Comparison
TBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TBIO stands at 532.8K. In comparison, PODD has a market cap of 22.1B. Regarding current trading prices, TBIO is priced at $0.30, while PODD trades at $314.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TBIO currently has a P/E ratio of -0.01, whereas PODD's P/E ratio is 56.61. In terms of profitability, TBIO's ROE is -2.80%, compared to PODD's ROE of +0.35%. Regarding short-term risk, TBIO is less volatile compared to PODD. This indicates potentially lower risk in terms of short-term price fluctuations for TBIO.
TBIO vs ZBH Comparison
TBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TBIO stands at 532.8K. In comparison, ZBH has a market cap of 18B. Regarding current trading prices, TBIO is priced at $0.30, while ZBH trades at $91.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TBIO currently has a P/E ratio of -0.01, whereas ZBH's P/E ratio is 20.27. In terms of profitability, TBIO's ROE is -2.80%, compared to ZBH's ROE of +0.07%. Regarding short-term risk, TBIO is less volatile compared to ZBH. This indicates potentially lower risk in terms of short-term price fluctuations for TBIO.
TBIO vs ABMD Comparison
TBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TBIO stands at 532.8K. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, TBIO is priced at $0.30, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TBIO currently has a P/E ratio of -0.01, whereas ABMD's P/E ratio is 65.36. In terms of profitability, TBIO's ROE is -2.80%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, TBIO is less volatile compared to ABMD. This indicates potentially lower risk in terms of short-term price fluctuations for TBIO.
TBIO vs ALGN Comparison
TBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TBIO stands at 532.8K. In comparison, ALGN has a market cap of 13.7B. Regarding current trading prices, TBIO is priced at $0.30, while ALGN trades at $189.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TBIO currently has a P/E ratio of -0.01, whereas ALGN's P/E ratio is 34.36. In terms of profitability, TBIO's ROE is -2.80%, compared to ALGN's ROE of +0.11%. Regarding short-term risk, TBIO is less volatile compared to ALGN. This indicates potentially lower risk in terms of short-term price fluctuations for TBIO.
TBIO vs SNN Comparison
TBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TBIO stands at 532.8K. In comparison, SNN has a market cap of 13.4B. Regarding current trading prices, TBIO is priced at $0.30, while SNN trades at $30.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TBIO currently has a P/E ratio of -0.01, whereas SNN's P/E ratio is 32.59. In terms of profitability, TBIO's ROE is -2.80%, compared to SNN's ROE of +0.08%. Regarding short-term risk, TBIO is less volatile compared to SNN. This indicates potentially lower risk in terms of short-term price fluctuations for TBIO.
TBIO vs SWAV Comparison
TBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TBIO stands at 532.8K. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, TBIO is priced at $0.30, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TBIO currently has a P/E ratio of -0.01, whereas SWAV's P/E ratio is 78.76. In terms of profitability, TBIO's ROE is -2.80%, compared to SWAV's ROE of +0.14%. Regarding short-term risk, TBIO is less volatile compared to SWAV. This indicates potentially lower risk in terms of short-term price fluctuations for TBIO.
TBIO vs PEN Comparison
TBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TBIO stands at 532.8K. In comparison, PEN has a market cap of 9.9B. Regarding current trading prices, TBIO is priced at $0.30, while PEN trades at $256.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TBIO currently has a P/E ratio of -0.01, whereas PEN's P/E ratio is 237.56. In terms of profitability, TBIO's ROE is -2.80%, compared to PEN's ROE of +0.04%. Regarding short-term risk, TBIO is less volatile compared to PEN. This indicates potentially lower risk in terms of short-term price fluctuations for TBIO.
TBIO vs GMED Comparison
TBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TBIO stands at 532.8K. In comparison, GMED has a market cap of 8B. Regarding current trading prices, TBIO is priced at $0.30, while GMED trades at $59.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TBIO currently has a P/E ratio of -0.01, whereas GMED's P/E ratio is 44.03. In terms of profitability, TBIO's ROE is -2.80%, compared to GMED's ROE of +0.05%. Regarding short-term risk, TBIO is less volatile compared to GMED. This indicates potentially lower risk in terms of short-term price fluctuations for TBIO.
TBIO vs BIO-B Comparison
TBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TBIO stands at 532.8K. In comparison, BIO-B has a market cap of 6.8B. Regarding current trading prices, TBIO is priced at $0.30, while BIO-B trades at $250.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TBIO currently has a P/E ratio of -0.01, whereas BIO-B's P/E ratio is -3.27. In terms of profitability, TBIO's ROE is -2.80%, compared to BIO-B's ROE of -0.32%. Regarding short-term risk, TBIO and BIO-B have similar daily volatility (0.00).
TBIO vs BIO Comparison
TBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TBIO stands at 532.8K. In comparison, BIO has a market cap of 6.6B. Regarding current trading prices, TBIO is priced at $0.30, while BIO trades at $241.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TBIO currently has a P/E ratio of -0.01, whereas BIO's P/E ratio is -3.15. In terms of profitability, TBIO's ROE is -2.80%, compared to BIO's ROE of -0.32%. Regarding short-term risk, TBIO is less volatile compared to BIO. This indicates potentially lower risk in terms of short-term price fluctuations for TBIO.
TBIO vs BRKR Comparison
TBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TBIO stands at 532.8K. In comparison, BRKR has a market cap of 6.2B. Regarding current trading prices, TBIO is priced at $0.30, while BRKR trades at $41.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TBIO currently has a P/E ratio of -0.01, whereas BRKR's P/E ratio is 79.23. In terms of profitability, TBIO's ROE is -2.80%, compared to BRKR's ROE of +0.04%. Regarding short-term risk, TBIO is less volatile compared to BRKR. This indicates potentially lower risk in terms of short-term price fluctuations for TBIO.
TBIO vs GKOS Comparison
TBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TBIO stands at 532.8K. In comparison, GKOS has a market cap of 5.9B. Regarding current trading prices, TBIO is priced at $0.30, while GKOS trades at $103.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TBIO currently has a P/E ratio of -0.01, whereas GKOS's P/E ratio is -45.52. In terms of profitability, TBIO's ROE is -2.80%, compared to GKOS's ROE of -0.17%. Regarding short-term risk, TBIO is less volatile compared to GKOS. This indicates potentially lower risk in terms of short-term price fluctuations for TBIO.
TBIO vs IRTC Comparison
TBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TBIO stands at 532.8K. In comparison, IRTC has a market cap of 4.9B. Regarding current trading prices, TBIO is priced at $0.30, while IRTC trades at $153.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TBIO currently has a P/E ratio of -0.01, whereas IRTC's P/E ratio is -49.35. In terms of profitability, TBIO's ROE is -2.80%, compared to IRTC's ROE of -1.13%. Regarding short-term risk, TBIO is less volatile compared to IRTC. This indicates potentially lower risk in terms of short-term price fluctuations for TBIO.
TBIO vs NARI Comparison
TBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TBIO stands at 532.8K. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, TBIO is priced at $0.30, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TBIO currently has a P/E ratio of -0.01, whereas NARI's P/E ratio is -59.24. In terms of profitability, TBIO's ROE is -2.80%, compared to NARI's ROE of -0.18%. Regarding short-term risk, TBIO is less volatile compared to NARI. This indicates potentially lower risk in terms of short-term price fluctuations for TBIO.
TBIO vs TMDX Comparison
TBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TBIO stands at 532.8K. In comparison, TMDX has a market cap of 4.5B. Regarding current trading prices, TBIO is priced at $0.30, while TMDX trades at $134.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TBIO currently has a P/E ratio of -0.01, whereas TMDX's P/E ratio is 94.37. In terms of profitability, TBIO's ROE is -2.80%, compared to TMDX's ROE of +0.22%. Regarding short-term risk, TBIO is less volatile compared to TMDX. This indicates potentially lower risk in terms of short-term price fluctuations for TBIO.
TBIO vs ITGR Comparison
TBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TBIO stands at 532.8K. In comparison, ITGR has a market cap of 4.3B. Regarding current trading prices, TBIO is priced at $0.30, while ITGR trades at $122.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TBIO currently has a P/E ratio of -0.01, whereas ITGR's P/E ratio is 57.45. In terms of profitability, TBIO's ROE is -2.80%, compared to ITGR's ROE of +0.05%. Regarding short-term risk, TBIO is less volatile compared to ITGR. This indicates potentially lower risk in terms of short-term price fluctuations for TBIO.
TBIO vs INSP Comparison
TBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TBIO stands at 532.8K. In comparison, INSP has a market cap of 3.8B. Regarding current trading prices, TBIO is priced at $0.30, while INSP trades at $129.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TBIO currently has a P/E ratio of -0.01, whereas INSP's P/E ratio is 59.21. In terms of profitability, TBIO's ROE is -2.80%, compared to INSP's ROE of +0.10%. Regarding short-term risk, TBIO is less volatile compared to INSP. This indicates potentially lower risk in terms of short-term price fluctuations for TBIO.
TBIO vs AXNX Comparison
TBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TBIO stands at 532.8K. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, TBIO is priced at $0.30, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TBIO currently has a P/E ratio of -0.01, whereas AXNX's P/E ratio is -709.80. In terms of profitability, TBIO's ROE is -2.80%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, TBIO and AXNX have similar daily volatility (0.00).
TBIO vs PRCT Comparison
TBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TBIO stands at 532.8K. In comparison, PRCT has a market cap of 3.2B. Regarding current trading prices, TBIO is priced at $0.30, while PRCT trades at $57.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TBIO currently has a P/E ratio of -0.01, whereas PRCT's P/E ratio is -34.08. In terms of profitability, TBIO's ROE is -2.80%, compared to PRCT's ROE of -0.28%. Regarding short-term risk, TBIO is less volatile compared to PRCT. This indicates potentially lower risk in terms of short-term price fluctuations for TBIO.
TBIO vs LIVN Comparison
TBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TBIO stands at 532.8K. In comparison, LIVN has a market cap of 2.5B. Regarding current trading prices, TBIO is priced at $0.30, while LIVN trades at $45.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TBIO currently has a P/E ratio of -0.01, whereas LIVN's P/E ratio is -11.06. In terms of profitability, TBIO's ROE is -2.80%, compared to LIVN's ROE of -0.18%. Regarding short-term risk, TBIO is less volatile compared to LIVN. This indicates potentially lower risk in terms of short-term price fluctuations for TBIO.
TBIO vs NUVA Comparison
TBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TBIO stands at 532.8K. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, TBIO is priced at $0.30, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TBIO currently has a P/E ratio of -0.01, whereas NUVA's P/E ratio is 75.00. In terms of profitability, TBIO's ROE is -2.80%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, TBIO is less volatile compared to NUVA. This indicates potentially lower risk in terms of short-term price fluctuations for TBIO.
TBIO vs UFPT Comparison
TBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TBIO stands at 532.8K. In comparison, UFPT has a market cap of 1.9B. Regarding current trading prices, TBIO is priced at $0.30, while UFPT trades at $244.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TBIO currently has a P/E ratio of -0.01, whereas UFPT's P/E ratio is 29.96. In terms of profitability, TBIO's ROE is -2.80%, compared to UFPT's ROE of +0.19%. Regarding short-term risk, TBIO is less volatile compared to UFPT. This indicates potentially lower risk in terms of short-term price fluctuations for TBIO.
TBIO vs ATEC Comparison
TBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TBIO stands at 532.8K. In comparison, ATEC has a market cap of 1.6B. Regarding current trading prices, TBIO is priced at $0.30, while ATEC trades at $11.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TBIO currently has a P/E ratio of -0.01, whereas ATEC's P/E ratio is -9.74. In terms of profitability, TBIO's ROE is -2.80%, compared to ATEC's ROE of -2.58%. Regarding short-term risk, TBIO is less volatile compared to ATEC. This indicates potentially lower risk in terms of short-term price fluctuations for TBIO.
TBIO vs CNMD Comparison
TBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TBIO stands at 532.8K. In comparison, CNMD has a market cap of 1.6B. Regarding current trading prices, TBIO is priced at $0.30, while CNMD trades at $52.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TBIO currently has a P/E ratio of -0.01, whereas CNMD's P/E ratio is 13.66. In terms of profitability, TBIO's ROE is -2.80%, compared to CNMD's ROE of +0.13%. Regarding short-term risk, TBIO is less volatile compared to CNMD. This indicates potentially lower risk in terms of short-term price fluctuations for TBIO.
TBIO vs AORT Comparison
TBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TBIO stands at 532.8K. In comparison, AORT has a market cap of 1.3B. Regarding current trading prices, TBIO is priced at $0.30, while AORT trades at $31.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TBIO currently has a P/E ratio of -0.01, whereas AORT's P/E ratio is -61.03. In terms of profitability, TBIO's ROE is -2.80%, compared to AORT's ROE of -0.07%. Regarding short-term risk, TBIO is less volatile compared to AORT. This indicates potentially lower risk in terms of short-term price fluctuations for TBIO.
TBIO vs HSKA Comparison
TBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TBIO stands at 532.8K. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, TBIO is priced at $0.30, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TBIO currently has a P/E ratio of -0.01, whereas HSKA's P/E ratio is -62.49. In terms of profitability, TBIO's ROE is -2.80%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, TBIO and HSKA have similar daily volatility (0.00).
TBIO vs AHCO Comparison
TBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TBIO stands at 532.8K. In comparison, AHCO has a market cap of 1.3B. Regarding current trading prices, TBIO is priced at $0.30, while AHCO trades at $9.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TBIO currently has a P/E ratio of -0.01, whereas AHCO's P/E ratio is 16.26. In terms of profitability, TBIO's ROE is -2.80%, compared to AHCO's ROE of +0.06%. Regarding short-term risk, TBIO is less volatile compared to AHCO. This indicates potentially lower risk in terms of short-term price fluctuations for TBIO.
TBIO vs TNDM Comparison
TBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TBIO stands at 532.8K. In comparison, TNDM has a market cap of 1.2B. Regarding current trading prices, TBIO is priced at $0.30, while TNDM trades at $18.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TBIO currently has a P/E ratio of -0.01, whereas TNDM's P/E ratio is -6.68. In terms of profitability, TBIO's ROE is -2.80%, compared to TNDM's ROE of -0.83%. Regarding short-term risk, TBIO is less volatile compared to TNDM. This indicates potentially lower risk in terms of short-term price fluctuations for TBIO.
TBIO vs ESTA Comparison
TBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TBIO stands at 532.8K. In comparison, ESTA has a market cap of 1.2B. Regarding current trading prices, TBIO is priced at $0.30, while ESTA trades at $42.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TBIO currently has a P/E ratio of -0.01, whereas ESTA's P/E ratio is -13.69. In terms of profitability, TBIO's ROE is -2.80%, compared to ESTA's ROE of -2.10%. Regarding short-term risk, TBIO is less volatile compared to ESTA. This indicates potentially lower risk in terms of short-term price fluctuations for TBIO.
TBIO vs SSII Comparison
TBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TBIO stands at 532.8K. In comparison, SSII has a market cap of 1.1B. Regarding current trading prices, TBIO is priced at $0.30, while SSII trades at $5.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TBIO currently has a P/E ratio of -0.01, whereas SSII's P/E ratio is -73.62. In terms of profitability, TBIO's ROE is -2.80%, compared to SSII's ROE of -1.33%. Regarding short-term risk, TBIO is less volatile compared to SSII. This indicates potentially lower risk in terms of short-term price fluctuations for TBIO.
TBIO vs SILK Comparison
TBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TBIO stands at 532.8K. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, TBIO is priced at $0.30, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TBIO currently has a P/E ratio of -0.01, whereas SILK's P/E ratio is -18.96. In terms of profitability, TBIO's ROE is -2.80%, compared to SILK's ROE of -0.29%. Regarding short-term risk, TBIO is less volatile compared to SILK. This indicates potentially lower risk in terms of short-term price fluctuations for TBIO.
TBIO vs FNA Comparison
TBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TBIO stands at 532.8K. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, TBIO is priced at $0.30, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TBIO currently has a P/E ratio of -0.01, whereas FNA's P/E ratio is -19.83. In terms of profitability, TBIO's ROE is -2.80%, compared to FNA's ROE of -0.36%. Regarding short-term risk, TBIO is less volatile compared to FNA. This indicates potentially lower risk in terms of short-term price fluctuations for TBIO.
TBIO vs INMD Comparison
TBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TBIO stands at 532.8K. In comparison, INMD has a market cap of 1B. Regarding current trading prices, TBIO is priced at $0.30, while INMD trades at $14.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TBIO currently has a P/E ratio of -0.01, whereas INMD's P/E ratio is 6.48. In terms of profitability, TBIO's ROE is -2.80%, compared to INMD's ROE of +0.25%. Regarding short-term risk, TBIO is less volatile compared to INMD. This indicates potentially lower risk in terms of short-term price fluctuations for TBIO.
TBIO vs IART Comparison
TBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TBIO stands at 532.8K. In comparison, IART has a market cap of 953.5M. Regarding current trading prices, TBIO is priced at $0.30, while IART trades at $12.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TBIO currently has a P/E ratio of -0.01, whereas IART's P/E ratio is -32.29. In terms of profitability, TBIO's ROE is -2.80%, compared to IART's ROE of -0.03%. Regarding short-term risk, TBIO is less volatile compared to IART. This indicates potentially lower risk in terms of short-term price fluctuations for TBIO.
TBIO vs CSII Comparison
TBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TBIO stands at 532.8K. In comparison, CSII has a market cap of 844M. Regarding current trading prices, TBIO is priced at $0.30, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TBIO currently has a P/E ratio of -0.01, whereas CSII's P/E ratio is -20.83. In terms of profitability, TBIO's ROE is -2.80%, compared to CSII's ROE of -0.14%. Regarding short-term risk, TBIO is less volatile compared to CSII. This indicates potentially lower risk in terms of short-term price fluctuations for TBIO.
TBIO vs SIBN Comparison
TBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TBIO stands at 532.8K. In comparison, SIBN has a market cap of 802M. Regarding current trading prices, TBIO is priced at $0.30, while SIBN trades at $18.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TBIO currently has a P/E ratio of -0.01, whereas SIBN's P/E ratio is -29.87. In terms of profitability, TBIO's ROE is -2.80%, compared to SIBN's ROE of -0.16%. Regarding short-term risk, TBIO is less volatile compared to SIBN. This indicates potentially lower risk in terms of short-term price fluctuations for TBIO.
TBIO vs IRMD Comparison
TBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TBIO stands at 532.8K. In comparison, IRMD has a market cap of 760.2M. Regarding current trading prices, TBIO is priced at $0.30, while IRMD trades at $59.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TBIO currently has a P/E ratio of -0.01, whereas IRMD's P/E ratio is 38.57. In terms of profitability, TBIO's ROE is -2.80%, compared to IRMD's ROE of +0.23%. Regarding short-term risk, TBIO is less volatile compared to IRMD. This indicates potentially lower risk in terms of short-term price fluctuations for TBIO.
TBIO vs CRY Comparison
TBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TBIO stands at 532.8K. In comparison, CRY has a market cap of 725.1M. Regarding current trading prices, TBIO is priced at $0.30, while CRY trades at $17.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TBIO currently has a P/E ratio of -0.01, whereas CRY's P/E ratio is 425.71. In terms of profitability, TBIO's ROE is -2.80%, compared to CRY's ROE of -0.07%. Regarding short-term risk, TBIO is less volatile compared to CRY. This indicates potentially lower risk in terms of short-term price fluctuations for TBIO.
TBIO vs CBLL Comparison
TBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TBIO stands at 532.8K. In comparison, CBLL has a market cap of 677M. Regarding current trading prices, TBIO is priced at $0.30, while CBLL trades at $18.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TBIO currently has a P/E ratio of -0.01, whereas CBLL's P/E ratio is -14.98. In terms of profitability, TBIO's ROE is -2.80%, compared to CBLL's ROE of -1.64%. Regarding short-term risk, TBIO is less volatile compared to CBLL. This indicates potentially lower risk in terms of short-term price fluctuations for TBIO.
TBIO vs APEN Comparison
TBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TBIO stands at 532.8K. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, TBIO is priced at $0.30, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TBIO currently has a P/E ratio of -0.01, whereas APEN's P/E ratio is -9.43. In terms of profitability, TBIO's ROE is -2.80%, compared to APEN's ROE of -0.85%. Regarding short-term risk, TBIO is less volatile compared to APEN. This indicates potentially lower risk in terms of short-term price fluctuations for TBIO.
TBIO vs AVNS Comparison
TBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TBIO stands at 532.8K. In comparison, AVNS has a market cap of 564.7M. Regarding current trading prices, TBIO is priced at $0.30, while AVNS trades at $12.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TBIO currently has a P/E ratio of -0.01, whereas AVNS's P/E ratio is -1.48. In terms of profitability, TBIO's ROE is -2.80%, compared to AVNS's ROE of -0.37%. Regarding short-term risk, TBIO is less volatile compared to AVNS. This indicates potentially lower risk in terms of short-term price fluctuations for TBIO.
TBIO vs KIDS Comparison
TBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TBIO stands at 532.8K. In comparison, KIDS has a market cap of 532M. Regarding current trading prices, TBIO is priced at $0.30, while KIDS trades at $21.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TBIO currently has a P/E ratio of -0.01, whereas KIDS's P/E ratio is -12.20. In terms of profitability, TBIO's ROE is -2.80%, compared to KIDS's ROE of -0.11%. Regarding short-term risk, TBIO is less volatile compared to KIDS. This indicates potentially lower risk in terms of short-term price fluctuations for TBIO.
TBIO vs RXST Comparison
TBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TBIO stands at 532.8K. In comparison, RXST has a market cap of 528.3M. Regarding current trading prices, TBIO is priced at $0.30, while RXST trades at $13.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TBIO currently has a P/E ratio of -0.01, whereas RXST's P/E ratio is -19.70. In terms of profitability, TBIO's ROE is -2.80%, compared to RXST's ROE of -0.10%. Regarding short-term risk, TBIO is less volatile compared to RXST. This indicates potentially lower risk in terms of short-term price fluctuations for TBIO.
TBIO vs BFLY-WT Comparison
TBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TBIO stands at 532.8K. In comparison, BFLY-WT has a market cap of 518.7M. Regarding current trading prices, TBIO is priced at $0.30, while BFLY-WT trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TBIO currently has a P/E ratio of -0.01, whereas BFLY-WT's P/E ratio is N/A. In terms of profitability, TBIO's ROE is -2.80%, compared to BFLY-WT's ROE of -0.33%. Regarding short-term risk, TBIO is less volatile compared to BFLY-WT. This indicates potentially lower risk in terms of short-term price fluctuations for TBIO.
TBIO vs AXGN Comparison
TBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TBIO stands at 532.8K. In comparison, AXGN has a market cap of 494.2M. Regarding current trading prices, TBIO is priced at $0.30, while AXGN trades at $10.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TBIO currently has a P/E ratio of -0.01, whereas AXGN's P/E ratio is -67.81. In terms of profitability, TBIO's ROE is -2.80%, compared to AXGN's ROE of -0.07%. Regarding short-term risk, TBIO is less volatile compared to AXGN. This indicates potentially lower risk in terms of short-term price fluctuations for TBIO.
TBIO vs BFLY Comparison
TBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TBIO stands at 532.8K. In comparison, BFLY has a market cap of 493.3M. Regarding current trading prices, TBIO is priced at $0.30, while BFLY trades at $2.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TBIO currently has a P/E ratio of -0.01, whereas BFLY's P/E ratio is -6.65. In terms of profitability, TBIO's ROE is -2.80%, compared to BFLY's ROE of -0.33%. Regarding short-term risk, TBIO is less volatile compared to BFLY. This indicates potentially lower risk in terms of short-term price fluctuations for TBIO.
TBIO vs BVS Comparison
TBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TBIO stands at 532.8K. In comparison, BVS has a market cap of 439.3M. Regarding current trading prices, TBIO is priced at $0.30, while BVS trades at $6.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TBIO currently has a P/E ratio of -0.01, whereas BVS's P/E ratio is -13.79. In terms of profitability, TBIO's ROE is -2.80%, compared to BVS's ROE of -0.21%. Regarding short-term risk, TBIO is less volatile compared to BVS. This indicates potentially lower risk in terms of short-term price fluctuations for TBIO.
TBIO vs OFIX Comparison
TBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TBIO stands at 532.8K. In comparison, OFIX has a market cap of 436.9M. Regarding current trading prices, TBIO is priced at $0.30, while OFIX trades at $11.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TBIO currently has a P/E ratio of -0.01, whereas OFIX's P/E ratio is -3.01. In terms of profitability, TBIO's ROE is -2.80%, compared to OFIX's ROE of -0.28%. Regarding short-term risk, TBIO is less volatile compared to OFIX. This indicates potentially lower risk in terms of short-term price fluctuations for TBIO.
TBIO vs SMLR Comparison
TBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TBIO stands at 532.8K. In comparison, SMLR has a market cap of 432M. Regarding current trading prices, TBIO is priced at $0.30, while SMLR trades at $38.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TBIO currently has a P/E ratio of -0.01, whereas SMLR's P/E ratio is -16.21. In terms of profitability, TBIO's ROE is -2.80%, compared to SMLR's ROE of -0.21%. Regarding short-term risk, TBIO is less volatile compared to SMLR. This indicates potentially lower risk in terms of short-term price fluctuations for TBIO.
TBIO vs CTKB Comparison
TBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TBIO stands at 532.8K. In comparison, CTKB has a market cap of 430.6M. Regarding current trading prices, TBIO is priced at $0.30, while CTKB trades at $3.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TBIO currently has a P/E ratio of -0.01, whereas CTKB's P/E ratio is -37.78. In terms of profitability, TBIO's ROE is -2.80%, compared to CTKB's ROE of -0.03%. Regarding short-term risk, TBIO is less volatile compared to CTKB. This indicates potentially lower risk in terms of short-term price fluctuations for TBIO.
TBIO vs SRDX Comparison
TBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TBIO stands at 532.8K. In comparison, SRDX has a market cap of 424.8M. Regarding current trading prices, TBIO is priced at $0.30, while SRDX trades at $29.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TBIO currently has a P/E ratio of -0.01, whereas SRDX's P/E ratio is -21.22. In terms of profitability, TBIO's ROE is -2.80%, compared to SRDX's ROE of -0.17%. Regarding short-term risk, TBIO is less volatile compared to SRDX. This indicates potentially lower risk in terms of short-term price fluctuations for TBIO.
TBIO vs PACB Comparison
TBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TBIO stands at 532.8K. In comparison, PACB has a market cap of 372.1M. Regarding current trading prices, TBIO is priced at $0.30, while PACB trades at $1.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TBIO currently has a P/E ratio of -0.01, whereas PACB's P/E ratio is -0.45. In terms of profitability, TBIO's ROE is -2.80%, compared to PACB's ROE of -1.70%. Regarding short-term risk, TBIO is less volatile compared to PACB. This indicates potentially lower risk in terms of short-term price fluctuations for TBIO.
TBIO vs TMCI Comparison
TBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TBIO stands at 532.8K. In comparison, TMCI has a market cap of 369.9M. Regarding current trading prices, TBIO is priced at $0.30, while TMCI trades at $5.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TBIO currently has a P/E ratio of -0.01, whereas TMCI's P/E ratio is -6.92. In terms of profitability, TBIO's ROE is -2.80%, compared to TMCI's ROE of -0.49%. Regarding short-term risk, TBIO is less volatile compared to TMCI. This indicates potentially lower risk in terms of short-term price fluctuations for TBIO.
TBIO vs NPCE Comparison
TBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TBIO stands at 532.8K. In comparison, NPCE has a market cap of 365.4M. Regarding current trading prices, TBIO is priced at $0.30, while NPCE trades at $11.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TBIO currently has a P/E ratio of -0.01, whereas NPCE's P/E ratio is -13.59. In terms of profitability, TBIO's ROE is -2.80%, compared to NPCE's ROE of -1.40%. Regarding short-term risk, TBIO is less volatile compared to NPCE. This indicates potentially lower risk in terms of short-term price fluctuations for TBIO.
TBIO vs VREX Comparison
TBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TBIO stands at 532.8K. In comparison, VREX has a market cap of 359.8M. Regarding current trading prices, TBIO is priced at $0.30, while VREX trades at $8.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TBIO currently has a P/E ratio of -0.01, whereas VREX's P/E ratio is -8.42. In terms of profitability, TBIO's ROE is -2.80%, compared to VREX's ROE of -0.08%. Regarding short-term risk, TBIO is less volatile compared to VREX. This indicates potentially lower risk in terms of short-term price fluctuations for TBIO.
TBIO vs SENS Comparison
TBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TBIO stands at 532.8K. In comparison, SENS has a market cap of 358.3M. Regarding current trading prices, TBIO is priced at $0.30, while SENS trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TBIO currently has a P/E ratio of -0.01, whereas SENS's P/E ratio is -4.32. In terms of profitability, TBIO's ROE is -2.80%, compared to SENS's ROE of -7.46%. Regarding short-term risk, TBIO is less volatile compared to SENS. This indicates potentially lower risk in terms of short-term price fluctuations for TBIO.
TBIO vs OM Comparison
TBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TBIO stands at 532.8K. In comparison, OM has a market cap of 340.4M. Regarding current trading prices, TBIO is priced at $0.30, while OM trades at $19.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TBIO currently has a P/E ratio of -0.01, whereas OM's P/E ratio is -0.67. In terms of profitability, TBIO's ROE is -2.80%, compared to OM's ROE of -1.45%. Regarding short-term risk, TBIO is less volatile compared to OM. This indicates potentially lower risk in terms of short-term price fluctuations for TBIO.
TBIO vs CLPT Comparison
TBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TBIO stands at 532.8K. In comparison, CLPT has a market cap of 337.5M. Regarding current trading prices, TBIO is priced at $0.30, while CLPT trades at $11.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TBIO currently has a P/E ratio of -0.01, whereas CLPT's P/E ratio is -15.71. In terms of profitability, TBIO's ROE is -2.80%, compared to CLPT's ROE of -0.78%. Regarding short-term risk, TBIO is less volatile compared to CLPT. This indicates potentially lower risk in terms of short-term price fluctuations for TBIO.
TBIO vs NNOX Comparison
TBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TBIO stands at 532.8K. In comparison, NNOX has a market cap of 329M. Regarding current trading prices, TBIO is priced at $0.30, while NNOX trades at $5.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TBIO currently has a P/E ratio of -0.01, whereas NNOX's P/E ratio is -5.67. In terms of profitability, TBIO's ROE is -2.80%, compared to NNOX's ROE of -0.31%. Regarding short-term risk, TBIO is less volatile compared to NNOX. This indicates potentially lower risk in terms of short-term price fluctuations for TBIO.
TBIO vs SNWV Comparison
TBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TBIO stands at 532.8K. In comparison, SNWV has a market cap of 281.1M. Regarding current trading prices, TBIO is priced at $0.30, while SNWV trades at $32.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TBIO currently has a P/E ratio of -0.01, whereas SNWV's P/E ratio is -5.27. In terms of profitability, TBIO's ROE is -2.80%, compared to SNWV's ROE of +1.00%. Regarding short-term risk, TBIO is less volatile compared to SNWV. This indicates potentially lower risk in terms of short-term price fluctuations for TBIO.
TBIO vs VMD Comparison
TBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TBIO stands at 532.8K. In comparison, VMD has a market cap of 273.1M. Regarding current trading prices, TBIO is priced at $0.30, while VMD trades at $6.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TBIO currently has a P/E ratio of -0.01, whereas VMD's P/E ratio is 23.03. In terms of profitability, TBIO's ROE is -2.80%, compared to VMD's ROE of +0.10%. Regarding short-term risk, TBIO is less volatile compared to VMD. This indicates potentially lower risk in terms of short-term price fluctuations for TBIO.
TBIO vs CERS Comparison
TBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TBIO stands at 532.8K. In comparison, CERS has a market cap of 269.5M. Regarding current trading prices, TBIO is priced at $0.30, while CERS trades at $1.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TBIO currently has a P/E ratio of -0.01, whereas CERS's P/E ratio is -14.10. In terms of profitability, TBIO's ROE is -2.80%, compared to CERS's ROE of -0.35%. Regarding short-term risk, TBIO is less volatile compared to CERS. This indicates potentially lower risk in terms of short-term price fluctuations for TBIO.
TBIO vs PTHL Comparison
TBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TBIO stands at 532.8K. In comparison, PTHL has a market cap of 262.1M. Regarding current trading prices, TBIO is priced at $0.30, while PTHL trades at $18.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TBIO currently has a P/E ratio of -0.01, whereas PTHL's P/E ratio is -367.80. In terms of profitability, TBIO's ROE is -2.80%, compared to PTHL's ROE of -0.30%. Regarding short-term risk, TBIO is less volatile compared to PTHL. This indicates potentially lower risk in terms of short-term price fluctuations for TBIO.
TBIO vs ZIMV Comparison
TBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TBIO stands at 532.8K. In comparison, ZIMV has a market cap of 261.1M. Regarding current trading prices, TBIO is priced at $0.30, while ZIMV trades at $9.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TBIO currently has a P/E ratio of -0.01, whereas ZIMV's P/E ratio is -10.39. In terms of profitability, TBIO's ROE is -2.80%, compared to ZIMV's ROE of -0.04%. Regarding short-term risk, TBIO is less volatile compared to ZIMV. This indicates potentially lower risk in terms of short-term price fluctuations for TBIO.
TBIO vs QTRX Comparison
TBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TBIO stands at 532.8K. In comparison, QTRX has a market cap of 258.4M. Regarding current trading prices, TBIO is priced at $0.30, while QTRX trades at $6.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TBIO currently has a P/E ratio of -0.01, whereas QTRX's P/E ratio is -5.36. In terms of profitability, TBIO's ROE is -2.80%, compared to QTRX's ROE of -0.15%. Regarding short-term risk, TBIO is less volatile compared to QTRX. This indicates potentially lower risk in terms of short-term price fluctuations for TBIO.
TBIO vs CATX Comparison
TBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TBIO stands at 532.8K. In comparison, CATX has a market cap of 256.1M. Regarding current trading prices, TBIO is priced at $0.30, while CATX trades at $3.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TBIO currently has a P/E ratio of -0.01, whereas CATX's P/E ratio is -2.80. In terms of profitability, TBIO's ROE is -2.80%, compared to CATX's ROE of -0.27%. Regarding short-term risk, TBIO is less volatile compared to CATX. This indicates potentially lower risk in terms of short-term price fluctuations for TBIO.
TBIO vs MASS Comparison
TBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TBIO stands at 532.8K. In comparison, MASS has a market cap of 255.7M. Regarding current trading prices, TBIO is priced at $0.30, while MASS trades at $7.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TBIO currently has a P/E ratio of -0.01, whereas MASS's P/E ratio is -3.21. In terms of profitability, TBIO's ROE is -2.80%, compared to MASS's ROE of -0.13%. Regarding short-term risk, TBIO is less volatile compared to MASS. This indicates potentially lower risk in terms of short-term price fluctuations for TBIO.
TBIO vs BWAY Comparison
TBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TBIO stands at 532.8K. In comparison, BWAY has a market cap of 248.5M. Regarding current trading prices, TBIO is priced at $0.30, while BWAY trades at $13.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TBIO currently has a P/E ratio of -0.01, whereas BWAY's P/E ratio is 59.77. In terms of profitability, TBIO's ROE is -2.80%, compared to BWAY's ROE of +0.06%. Regarding short-term risk, TBIO is less volatile compared to BWAY. This indicates potentially lower risk in terms of short-term price fluctuations for TBIO.
TBIO vs TCMD Comparison
TBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TBIO stands at 532.8K. In comparison, TCMD has a market cap of 235.7M. Regarding current trading prices, TBIO is priced at $0.30, while TCMD trades at $10.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TBIO currently has a P/E ratio of -0.01, whereas TCMD's P/E ratio is 15.36. In terms of profitability, TBIO's ROE is -2.80%, compared to TCMD's ROE of +0.08%. Regarding short-term risk, TBIO is less volatile compared to TCMD. This indicates potentially lower risk in terms of short-term price fluctuations for TBIO.
TBIO vs MXCT Comparison
TBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TBIO stands at 532.8K. In comparison, MXCT has a market cap of 231.8M. Regarding current trading prices, TBIO is priced at $0.30, while MXCT trades at $2.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TBIO currently has a P/E ratio of -0.01, whereas MXCT's P/E ratio is -5.45. In terms of profitability, TBIO's ROE is -2.80%, compared to MXCT's ROE of -0.20%. Regarding short-term risk, TBIO is less volatile compared to MXCT. This indicates potentially lower risk in terms of short-term price fluctuations for TBIO.
TBIO vs NVRO Comparison
TBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TBIO stands at 532.8K. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, TBIO is priced at $0.30, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TBIO currently has a P/E ratio of -0.01, whereas NVRO's P/E ratio is -1.91. In terms of profitability, TBIO's ROE is -2.80%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, TBIO is less volatile compared to NVRO. This indicates potentially lower risk in terms of short-term price fluctuations for TBIO.
TBIO vs SGHT Comparison
TBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TBIO stands at 532.8K. In comparison, SGHT has a market cap of 213.5M. Regarding current trading prices, TBIO is priced at $0.30, while SGHT trades at $4.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TBIO currently has a P/E ratio of -0.01, whereas SGHT's P/E ratio is -4.21. In terms of profitability, TBIO's ROE is -2.80%, compared to SGHT's ROE of -0.55%. Regarding short-term risk, TBIO is less volatile compared to SGHT. This indicates potentially lower risk in terms of short-term price fluctuations for TBIO.
TBIO vs EYES Comparison
TBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TBIO stands at 532.8K. In comparison, EYES has a market cap of 210M. Regarding current trading prices, TBIO is priced at $0.30, while EYES trades at $4.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TBIO currently has a P/E ratio of -0.01, whereas EYES's P/E ratio is N/A. In terms of profitability, TBIO's ROE is -2.80%, compared to EYES's ROE of -0.26%. Regarding short-term risk, TBIO is less volatile compared to EYES. This indicates potentially lower risk in terms of short-term price fluctuations for TBIO.
TBIO vs TLSI Comparison
TBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TBIO stands at 532.8K. In comparison, TLSI has a market cap of 207M. Regarding current trading prices, TBIO is priced at $0.30, while TLSI trades at $5.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TBIO currently has a P/E ratio of -0.01, whereas TLSI's P/E ratio is -4.95. In terms of profitability, TBIO's ROE is -2.80%, compared to TLSI's ROE of +1.04%. Regarding short-term risk, TBIO is less volatile compared to TLSI. This indicates potentially lower risk in terms of short-term price fluctuations for TBIO.
TBIO vs BSGM Comparison
TBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TBIO stands at 532.8K. In comparison, BSGM has a market cap of 194.9M. Regarding current trading prices, TBIO is priced at $0.30, while BSGM trades at $7.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TBIO currently has a P/E ratio of -0.01, whereas BSGM's P/E ratio is -13.47. In terms of profitability, TBIO's ROE is -2.80%, compared to BSGM's ROE of -35.30%. Regarding short-term risk, TBIO is less volatile compared to BSGM. This indicates potentially lower risk in terms of short-term price fluctuations for TBIO.
TBIO vs INGN Comparison
TBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TBIO stands at 532.8K. In comparison, INGN has a market cap of 189M. Regarding current trading prices, TBIO is priced at $0.30, while INGN trades at $7.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TBIO currently has a P/E ratio of -0.01, whereas INGN's P/E ratio is -6.11. In terms of profitability, TBIO's ROE is -2.80%, compared to INGN's ROE of -0.15%. Regarding short-term risk, TBIO is less volatile compared to INGN. This indicates potentially lower risk in terms of short-term price fluctuations for TBIO.
TBIO vs ELMD Comparison
TBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TBIO stands at 532.8K. In comparison, ELMD has a market cap of 184.9M. Regarding current trading prices, TBIO is priced at $0.30, while ELMD trades at $21.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TBIO currently has a P/E ratio of -0.01, whereas ELMD's P/E ratio is 27.91. In terms of profitability, TBIO's ROE is -2.80%, compared to ELMD's ROE of +0.17%. Regarding short-term risk, TBIO is less volatile compared to ELMD. This indicates potentially lower risk in terms of short-term price fluctuations for TBIO.
TBIO vs PROF Comparison
TBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TBIO stands at 532.8K. In comparison, PROF has a market cap of 177.3M. Regarding current trading prices, TBIO is priced at $0.30, while PROF trades at $5.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TBIO currently has a P/E ratio of -0.01, whereas PROF's P/E ratio is -4.88. In terms of profitability, TBIO's ROE is -2.80%, compared to PROF's ROE of -0.70%. Regarding short-term risk, TBIO is less volatile compared to PROF. This indicates potentially lower risk in terms of short-term price fluctuations for TBIO.
TBIO vs LNSR Comparison
TBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TBIO stands at 532.8K. In comparison, LNSR has a market cap of 156.8M. Regarding current trading prices, TBIO is priced at $0.30, while LNSR trades at $13.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TBIO currently has a P/E ratio of -0.01, whereas LNSR's P/E ratio is -2.71. In terms of profitability, TBIO's ROE is -2.80%, compared to LNSR's ROE of -5.28%. Regarding short-term risk, TBIO is less volatile compared to LNSR. This indicates potentially lower risk in terms of short-term price fluctuations for TBIO.
TBIO vs CVRX Comparison
TBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TBIO stands at 532.8K. In comparison, CVRX has a market cap of 153.3M. Regarding current trading prices, TBIO is priced at $0.30, while CVRX trades at $5.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TBIO currently has a P/E ratio of -0.01, whereas CVRX's P/E ratio is -2.75. In terms of profitability, TBIO's ROE is -2.80%, compared to CVRX's ROE of -0.79%. Regarding short-term risk, TBIO is less volatile compared to CVRX. This indicates potentially lower risk in terms of short-term price fluctuations for TBIO.
TBIO vs ANIK Comparison
TBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TBIO stands at 532.8K. In comparison, ANIK has a market cap of 151.7M. Regarding current trading prices, TBIO is priced at $0.30, while ANIK trades at $10.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TBIO currently has a P/E ratio of -0.01, whereas ANIK's P/E ratio is -14.11. In terms of profitability, TBIO's ROE is -2.80%, compared to ANIK's ROE of -0.33%. Regarding short-term risk, TBIO is less volatile compared to ANIK. This indicates potentially lower risk in terms of short-term price fluctuations for TBIO.
TBIO vs RPID Comparison
TBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TBIO stands at 532.8K. In comparison, RPID has a market cap of 151.2M. Regarding current trading prices, TBIO is priced at $0.30, while RPID trades at $3.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TBIO currently has a P/E ratio of -0.01, whereas RPID's P/E ratio is -3.35. In terms of profitability, TBIO's ROE is -2.80%, compared to RPID's ROE of -0.56%. Regarding short-term risk, TBIO is less volatile compared to RPID. This indicates potentially lower risk in terms of short-term price fluctuations for TBIO.
TBIO vs AVR Comparison
TBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TBIO stands at 532.8K. In comparison, AVR has a market cap of 141.4M. Regarding current trading prices, TBIO is priced at $0.30, while AVR trades at $3.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TBIO currently has a P/E ratio of -0.01, whereas AVR's P/E ratio is -1.09. In terms of profitability, TBIO's ROE is -2.80%, compared to AVR's ROE of -2.92%. Regarding short-term risk, TBIO is less volatile compared to AVR. This indicates potentially lower risk in terms of short-term price fluctuations for TBIO.
TBIO vs RCEL Comparison
TBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TBIO stands at 532.8K. In comparison, RCEL has a market cap of 139.8M. Regarding current trading prices, TBIO is priced at $0.30, while RCEL trades at $5.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TBIO currently has a P/E ratio of -0.01, whereas RCEL's P/E ratio is -2.42. In terms of profitability, TBIO's ROE is -2.80%, compared to RCEL's ROE of -3.38%. Regarding short-term risk, TBIO is less volatile compared to RCEL. This indicates potentially lower risk in terms of short-term price fluctuations for TBIO.
TBIO vs OWLT Comparison
TBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TBIO stands at 532.8K. In comparison, OWLT has a market cap of 138.4M. Regarding current trading prices, TBIO is priced at $0.30, while OWLT trades at $8.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TBIO currently has a P/E ratio of -0.01, whereas OWLT's P/E ratio is -5.20. In terms of profitability, TBIO's ROE is -2.80%, compared to OWLT's ROE of +1.25%. Regarding short-term risk, TBIO is less volatile compared to OWLT. This indicates potentially lower risk in terms of short-term price fluctuations for TBIO.
TBIO vs BDMD Comparison
TBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TBIO stands at 532.8K. In comparison, BDMD has a market cap of 130.9M. Regarding current trading prices, TBIO is priced at $0.30, while BDMD trades at $3.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TBIO currently has a P/E ratio of -0.01, whereas BDMD's P/E ratio is 7.48. In terms of profitability, TBIO's ROE is -2.80%, compared to BDMD's ROE of +0.12%. Regarding short-term risk, TBIO is less volatile compared to BDMD. This indicates potentially lower risk in terms of short-term price fluctuations for TBIO.
TBIO vs LUCD Comparison
TBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TBIO stands at 532.8K. In comparison, LUCD has a market cap of 124.4M. Regarding current trading prices, TBIO is priced at $0.30, while LUCD trades at $1.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TBIO currently has a P/E ratio of -0.01, whereas LUCD's P/E ratio is -0.98. In terms of profitability, TBIO's ROE is -2.80%, compared to LUCD's ROE of +26.96%. Regarding short-term risk, TBIO is less volatile compared to LUCD. This indicates potentially lower risk in terms of short-term price fluctuations for TBIO.
TBIO vs ICAD Comparison
TBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TBIO stands at 532.8K. In comparison, ICAD has a market cap of 104.7M. Regarding current trading prices, TBIO is priced at $0.30, while ICAD trades at $3.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TBIO currently has a P/E ratio of -0.01, whereas ICAD's P/E ratio is -20.05. In terms of profitability, TBIO's ROE is -2.80%, compared to ICAD's ROE of -0.17%. Regarding short-term risk, TBIO is less volatile compared to ICAD. This indicates potentially lower risk in terms of short-term price fluctuations for TBIO.
TBIO vs LUNG Comparison
TBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TBIO stands at 532.8K. In comparison, LUNG has a market cap of 104.3M. Regarding current trading prices, TBIO is priced at $0.30, while LUNG trades at $2.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TBIO currently has a P/E ratio of -0.01, whereas LUNG's P/E ratio is -1.80. In terms of profitability, TBIO's ROE is -2.80%, compared to LUNG's ROE of -0.64%. Regarding short-term risk, TBIO is less volatile compared to LUNG. This indicates potentially lower risk in terms of short-term price fluctuations for TBIO.
TBIO vs MGRM Comparison
TBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TBIO stands at 532.8K. In comparison, MGRM has a market cap of 103.1M. Regarding current trading prices, TBIO is priced at $0.30, while MGRM trades at $2.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TBIO currently has a P/E ratio of -0.01, whereas MGRM's P/E ratio is -5.78. In terms of profitability, TBIO's ROE is -2.80%, compared to MGRM's ROE of -1.26%. Regarding short-term risk, TBIO is less volatile compared to MGRM. This indicates potentially lower risk in terms of short-term price fluctuations for TBIO.